Northrop Grumman Corporation
NOC
$526.06
-1.96%
Northrop Grumman Corporation is a leading global aerospace and defense contractor, providing a diversified portfolio of aeronautics, defense, mission, and space systems. The company is a prime contractor and key supplier on major U.S. defense programs, including the B-21 Raider stealth bomber, the F-35 fighter jet fuselage, and advanced missile defense and space systems. The current investor narrative is dominated by the prospect of a significant, multi-year surge in U.S. defense spending, potentially reaching Cold War-era levels, which is expected to drive long-term revenue growth for its high-margin programs. However, this optimism is tempered by recent stock volatility and concerns over supply chain dependencies, particularly on Chinese rare earth materials critical for weapons systems, which could pressure margins and execution.…
NOC
Northrop Grumman Corporation
$526.06
Related headlines
Investment Opinion: Should I buy NOC Today?
Rating & Thesis: Hold. Northrop Grumman presents a conflicted picture where strong fundamental tailwinds are currently overshadowed by severe technical deterioration and near-term execution risks, making it prudent to wait for a clearer entry point or evidence of trend stabilization. This is consistent with a 'Hold' stance, acknowledging the positive analyst sentiment (multiple 'Buy' reiterations) but prioritizing risk management given the 22% three-month decline.
Supporting Evidence: The valuation is mixed; the forward P/E of 18.70x is reasonable for a defense prime but not a deep discount, and the price-to-sales ratio of 1.95 provides a baseline for peer comparison. Revenue growth is solid at 9.6% YoY and accelerated through fiscal 2025. Profitability is a strength, with a net margin of 12.18% in Q4 and a superb ROE of 25.08%. However, the implied upside is unclear without a specific analyst target price, and the stock's dramatic underperformance (-32.46 relative strength over 3 months) suggests institutional sentiment has turned negative despite these fundamentals.
Risks & Conditions: The two biggest risks are 1) continued technical breakdown below key support at $472, signaling a deeper fundamental re-rating, and 2) supply chain-induced margin pressure eroding the 12.18% net margin. This Hold would upgrade to a Buy if the stock stabilizes above $600 on sustained volume, indicating the downtrend has broken, or if Q1 2026 earnings demonstrate resilient margins despite supply chain headlines. It would downgrade to a Sell if revenue growth decelerates below 5% or if the debt-to-equity ratio climbs above 1.3. Relative to its own history and the sector, the stock is currently fairly valued, trading between its recent speculative highs and crisis-era lows, reflecting a market pricing in steady growth but significant execution risk.
Sign up to view all
NOC 12-Month Price Forecast
The AI assessment is neutral with medium confidence. The fundamental setup is attractive, characterized by accelerating revenue, robust cash flow, and a powerful secular tailwind. However, the severe technical damage and clear shift in market sentiment cannot be ignored. The stock is in a corrective phase that may not be complete until it finds durable support. The stance would upgrade to bullish on a confirmed technical reversal above $700 accompanied by stable or expanding margins. It would turn bearish if the stock breaks below its 52-week low of $472, which would signal the growth narrative is fundamentally broken. The next 1-2 earnings reports are critical to determine which path prevails.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Northrop Grumman Corporation's 12-month outlook, with a consensus price target around $683.88 and implied upside of +30.0% versus the current price.
Average Target
$683.88
8 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
8
covering this stock
Price Range
$421 - $684
Analyst target range
Analyst coverage for Northrop Grumman is robust, with 8 analysts providing estimates, and recent institutional ratings show a predominantly bullish stance with multiple 'Buy' or 'Outperform' reiterations from firms like UBS, Citigroup, and RBC Capital in January 2026. The consensus sentiment is positive, with an average EPS estimate of $36.95 for the coming period, implying confidence in the company's earnings trajectory. The target price range from the estimated revenue data suggests a high degree of analyst conviction in the company's fundamental outlook, with revenue estimates clustering between $54.33 billion and $55.99 billion, indicating low dispersion and strong agreement on the growth path driven by defense budget tailwinds.
Bulls vs Bears: NOC Investment Factors
The investment debate for Northrop Grumman is a classic clash between strong fundamentals and deteriorating technicals. The bull case is anchored in a powerful, multi-year secular tailwind from rising defense budgets, robust profitability, and strong analyst conviction. The bear case is driven by a severe technical breakdown, supply chain vulnerabilities, and valuation that, while compressed, still embeds high growth expectations. Currently, the bearish technical momentum and external risk factors hold stronger evidence, as the stock's 22% three-month decline and severe underperformance signal a fundamental re-rating is underway. The single most important tension is whether the anticipated surge in defense spending can materialize quickly and profitably enough to overcome the near-term headwinds of supply chain disruption and investor sentiment shift. The resolution of this tension, visible in upcoming quarterly execution and margin trends, will determine the stock's direction.
Bullish
- Strong Defense Spending Tailwinds: Management has explicitly stated that U.S. defense spending could reach Cold War-era levels, creating a multi-year, high-margin revenue stream. This is evidenced by Q4 revenue growth of 9.6% YoY, accelerating sequentially from Q1, and analyst revenue estimates clustering tightly around $55 billion, indicating strong agreement on the growth path.
- Robust Profitability & Cash Flow: The company generates substantial free cash flow ($3.31 billion TTM) and has a high return on equity of 25.08%. Net income improved sequentially from $481 million in Q1 to $1.43 billion in Q4, demonstrating strong operational execution and margin expansion.
- Analyst Conviction & Positive Sentiment: Analyst coverage is robust with 8 analysts, and recent institutional ratings show a predominantly bullish stance with multiple 'Buy' or 'Outperform' reiterations. The average EPS estimate of $36.95 implies confidence in the earnings trajectory, supported by a forward P/E of 18.7x.
- Diversified High-Profile Program Portfolio: Revenue is well-diversified across four segments (Aeronautics, Mission Systems, Space Systems, Defense Systems), with exposure to flagship programs like the B-21 Raider and F-35. This diversification mitigates single-program risk and provides multiple growth avenues.
Bearish
- Severe Technical Downtrend & Underperformance: The stock is in a pronounced downtrend, down 22.18% over the past three months and underperforming the S&P 500 by 32.46 percentage points. Trading 27% below its 52-week high of $774, it shows clear momentum reversal and institutional selling pressure.
- Supply Chain & Margin Risks: Heavy reliance on Chinese rare earth materials for critical weapons systems poses a significant execution risk, potentially pressuring margins. Gross margin of 19.6% and operating margin of 10.2% are already reflective of the competitive, cost-plus nature of defense contracting, leaving limited room for error.
- Valuation Compression from Recent Highs: While the trailing P/E of 19.57x is not deeply discounted, it represents a significant compression from peak multiples above 30x seen in early 2025. The stock's PEG ratio of 7.41 suggests the market is pricing in high growth expectations that may be vulnerable to disappointment.
- High Leverage & Macro Sensitivity: A debt-to-equity ratio of 1.18 indicates moderate leverage, which could pressure financial flexibility in a rising rate environment. Despite a low beta of -0.113, the stock has experienced a maximum drawdown of -29.6%, showing it is not immune to significant downside moves.
NOC Technical Analysis
The stock is in a pronounced downtrend from its recent highs, having declined 22.18% over the past three months and 1.53% over the past month, significantly underperforming the broader market, as evidenced by a -32.46 relative strength figure over three months. With a current price of $563.68, the stock is trading approximately 27% below its 52-week high of $774.00 and about 19% above its 52-week low of $472.02, positioning it in the lower-middle portion of its annual range and suggesting the momentum-driven rally has decisively reversed. Recent momentum is starkly negative and diverges from the still-positive 1-year return of 17.58%, indicating a sharp correction or trend reversal is underway; the stock's 1-month decline of 1.53% contrasts with the S&P 500's 6.31% gain, highlighting severe relative weakness and potential institutional selling. The stock's beta of -0.113 suggests it has exhibited low correlation and lower volatility than the market recently, though the dramatic 29.6% maximum drawdown from its peak shows it is not immune to significant downside moves. Key technical support lies at the 52-week low of $472.02, while resistance is at the recent high of $774.00; a sustained breakdown below the $472 support could signal a deeper fundamental re-rating, while a recovery above the $700 level would be needed to suggest the downtrend has abated.
Beta
-0.11
-0.11x market volatility
Max Drawdown
-31.5%
Largest decline past year
52-Week Range
$472-$774
Price range past year
Annual Return
+7.8%
Cumulative gain past year
| Period | NOC Return | S&P 500 |
|---|---|---|
| 1m | -7.2% | +5.0% |
| 3m | -28.9% | +10.7% |
| 6m | -4.2% | +10.0% |
| 1y | +7.8% | +26.5% |
| ytd | -10.2% | +10.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
NOC Fundamental Analysis
Revenue growth is solid, with Q4 2025 revenue of $11.71 billion representing a 9.6% year-over-year increase, and sequential quarterly revenue has grown from $9.47 billion in Q1 to the Q4 peak, indicating a steady acceleration through the fiscal year. The Aeronautics segment was the largest contributor in the latest period at $3.92 billion, followed by Mission Systems at $3.45 billion, Space Systems at $2.86 billion, and Defense Systems at $2.15 billion, showcasing diversified growth drivers. The company is highly profitable, with Q4 net income of $1.43 billion and a net margin of 12.18%, though gross margin of 19.6% and operating margin of 10.2% reflect the competitive and cost-plus nature of defense contracting. Profitability has improved sequentially, with net income rising from $481 million in Q1 to $1.43 billion in Q4, and the trailing twelve-month free cash flow of $3.31 billion provides strong internal funding capacity. The balance sheet carries moderate leverage with a debt-to-equity ratio of 1.18, but financial health is supported by a robust return on equity of 25.08% and a current ratio of 1.09, indicating adequate short-term liquidity; the substantial free cash flow yield supports continued shareholder returns via dividends and buybacks.
Quarterly Revenue
$11.7B
2025-12
Revenue YoY Growth
+0.09%
YoY Comparison
Gross Margin
+0.19%
Latest Quarter
Free Cash Flow
$3.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is NOC Overvalued?
Given the company's consistent profitability, the primary valuation metric is the P/E ratio. The trailing P/E stands at 19.57x, while the forward P/E is slightly lower at 18.70x, indicating the market expects modest earnings growth. Compared to sector averages, Northrop Grumman's valuation presents a mixed picture; its trailing P/E of 19.57x is above the Industrials sector average implied by its own historical data, and its price-to-sales ratio of 1.95 and EV/EBITDA of 13.49 are key benchmarks for peer comparison. Historically, the stock's current trailing P/E of 19.57x sits below its own 5-year peak levels seen above 30x in early 2025 but is above the low-teens multiples seen in late 2024, suggesting the valuation has compressed from optimistic highs but is not yet at deeply discounted levels, reflecting a market that is pricing in steady growth but not a major reacceleration.
PE
19.6x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -33x~38x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Northrop Grumman's primary financial risk is its moderate leverage, with a debt-to-equity ratio of 1.18, which could constrain capital allocation flexibility if interest rates remain elevated. Operationally, the company faces margin pressure from its reliance on complex, cost-plus contracts, as evidenced by a gross margin of 19.6% and an operating margin of 10.2%. Furthermore, while revenue is diversified, the company is heavily dependent on U.S. government spending cycles, and any budget delays or reallocations could impact the steady 9.6% YoY revenue growth trajectory. The substantial free cash flow of $3.31 billion provides a buffer, but earnings volatility is a concern, as net income swung from $481 million in Q1 to $1.43 billion in Q4.
Market & Competitive Risks: The stock's valuation presents a key market risk. Its trailing P/E of 19.57x, while below its own historical peak, is above the Industrials sector average, creating vulnerability to multiple compression if growth decelerates. The PEG ratio of 7.41 indicates the market is pricing in very high future growth, leaving little room for error. Competitively, the defense sector is seeing new entrants like SpaceX and Rocket Lab competing for next-generation contracts (e.g., missile defense 'Golden Dome'), potentially eroding NOC's traditional moat. Recent news highlights a critical supply chain risk: heavy dependence on Chinese rare earths, which could lead to cost inflation and program delays as the Pentagon mandates a reshoring by 2027.
Worst-Case Scenario: The worst-case scenario involves a combination of program execution missteps on flagship projects like the B-21, exacerbated by supply chain disruptions from Chinese rare earth export controls, leading to margin compression and missed earnings. Concurrently, a political shift or budget sequestration could delay the anticipated defense spending surge. This could trigger a wave of analyst downgrades from the current bullish consensus. In this adverse scenario, the stock could realistically re-test its 52-week low of $472.02, representing a downside of approximately -16% from the current price of $563.68. Given the stock's history of a -29.6% maximum drawdown, a move toward the $470-$500 range is a plausible bear-case outcome.
FAQ
The key risks are, in order of severity: 1) Execution & Supply Chain Risk: Heavy reliance on Chinese rare earths could disrupt production and pressure margins, as highlighted in recent news. 2) Budget & Political Risk: The anticipated defense spending surge is subject to political approval and could be delayed or scaled back. 3) Valuation Risk: The stock's PEG ratio of 7.41 leaves it vulnerable to multiple compression if growth disappoints. 4) Technical Risk: The stock is in a pronounced downtrend, down 22% in three months, which can become a self-fulfilling prophecy through institutional selling and negative sentiment.
The 12-month forecast presents three scenarios. The base case (60% probability) sees a recovery to a range of $600-$700, driven by steady defense budget growth and reliable execution, aligning with analyst consensus for earnings growth. The bull case (25% probability) targets a return to the prior high of $774 and beyond, catalyzed by a massive defense budget increase and flawless program execution. The bear case (15% probability) risks a decline to the $472-$550 range if budgets stall and supply chain issues worsen. The base case is most likely, assuming the company navigates near-term headwinds without major setbacks.
NOC is fairly valued relative to its near-term prospects but was previously overvalued at its peak. The current trailing P/E of 19.57x and forward P/E of 18.70x are reasonable for a defense prime with 9.6% revenue growth and a 25% ROE, but not a deep discount. The PEG ratio of 7.41 suggests the market is pricing in very high future growth, indicating expectations are elevated. Compared to its own history, the multiple has compressed from above 30x, moving from overvalued to fair value. The valuation implies the market expects steady execution on growth programs but is no longer willing to pay a premium for speculative budget optimism.
NOC is a Hold, not a clear buy at current levels. For long-term investors with a 3-5 year horizon who believe in the defense spending surge, the current 27% discount from the 52-week high may represent a future opportunity, but the severe technical downtrend and supply chain risks advise caution. The stock's 22% decline over three months signals a breakdown in momentum that typically precedes a period of consolidation or further weakness. A good buying opportunity would emerge on evidence of trend stabilization, such as a sustained move above $600, or a more attractive valuation closer to a forward P/E of 16x.
NOC is suitable only for long-term investment with a minimum holding period of 3-5 years. Its value proposition is tied to multi-year defense budget cycles and program execution, not short-term trading catalysts. The stock's low beta of -0.113 and 1.58% dividend yield support a buy-and-hold approach for income-oriented growth investors. Given the current severe technical downtrend and volatility evidenced by a 29.6% max drawdown, short-term trading is exceptionally risky. Investors should be prepared to withstand further near-term volatility while waiting for the long-term fundamental thesis on defense spending to play out.